US Stock MarketDetailed Quotes
ARMP Armata Pharmaceuticals
- 1.950
- -0.030-1.52%
Close Dec 20 16:00 ET
70.56MMarket Cap-1.70P/E (TTM)
2.000High1.900Low12.09KVolume1.910Open1.980Pre Close23.62KTurnover0.11%Turnover RatioLossP/E (Static)36.18MShares4.48052wk High-1.38P/B21.52MFloat Cap1.89052wk Low--Dividend TTM11.04MShs Float392.000Historical High--Div YieldTTM5.05%Amplitude0.001Historical Low1.954Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Armata Pharmaceuticals Stock Forum
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Thursday, 19th December at 7:00 am
Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Armata Pharmaceutic...
Armata Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Innoviva, Inc(85.2%),Innoviva Strategic Opportunities LLC(62.1%)
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025
LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology compan...
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding From the U.S. Department of Defense to Support Ongoing Disarm Clinical Trial of AP-SA02
$Dow Jones Industrial Average (.DJI.US)$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index (.SPX.US)$ fell by 1.39%, and the $Nasdaq Composite Index (.IXIC.US)$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth (UNH.US)$, $Johnson & Johnson (JNJ.US)$, and $Cisco (CSCO.US)$ l...
The second reason for is Armata’s diligence in preparing for future studies. The company i...
$NN Inc (NNBR.US)$ AH up 12% may look for lower entry or risk management will help
No comment yet